The study, conducted at Cerrahpaşa Medical Faculty in Istanbul and approved by the institutional review board there, retrospectively evaluated the clinical and follow-up records of patients diagnosed and managed at the centre over a ten-year period. Engin performed the skin biopsies, diagnosed and treated the patients, and led the manuscript; Yildirim assisted with follow-up and drafted the text; Erkoc classified treatments and staging and analysed the data. The work was carried out in accordance with the Declaration of Helsinki, and the authors report no conflicts of interest. As is typical for retrospective cohort analyses of rare lymphomas, the value of the dataset lies less in dramatic new findings than in the granular picture it paints of how one busy dermatology service handles a diagnostically treacherous disease over time.

Technically, mycosis fungoides belongs to the primary cutaneous lymphomas, a family of extranodal non-Hodgkin lymphomas that arise in the skin rather than in lymphoid organs. The current diagnostic framework is anchored by the 2018 update of the WHO-EORTC classification, which separates indolent entities such as early-stage mycosis fungoides from aggressive ones such as Sézary syndrome, the leukemic variant characterised by widespread erythroderma, circulating malignant T cells and a markedly worse prognosis. The International Consensus Classification of mature lymphoid neoplasms, published in 2022, further refined this landscape. Within that framework, mycosis fungoides follows a characteristic clinical course: patch-stage lesions progress to plaques, then potentially to tumours, and in a minority of patients to visceral involvement. Most patients, however, never advance beyond the early stages, which is why accurate staging at diagnosis is the single most important prognostic exercise.

That staging depends on a synthesis of clinical, histopathological and, where indicated, molecular data. Skin biopsies are examined for epidermotropism, the migration of atypical T lymphocytes into the epidermis, and for the formation of Pautrier microabscesses, small clusters of these cells that are highly characteristic though not always present. T-cell receptor gene rearrangement studies can demonstrate clonality, distinguishing a malignant population from a reactive infiltrate, but early lesions may lack convincing clonal evidence, forcing clinicians to repeat biopsies over months or years. Blood tests assess for Sézary cells, and in advanced cases, imaging and lymph node biopsy complete the tumour-node-metastasis-blood staging algorithm. The Istanbul study reflects this layered diagnostic process, with the corresponding author personally performing and interpreting the skin biopsies that anchored each patient’s diagnosis.

One of the best-documented problems in the field is diagnostic delay. A frequently cited Danish study by Skov and Gniadecki found that the histopathological diagnosis of mycosis fungoides is often delayed, with patients carrying the disease for years before a biopsy confirms it, partly because early histology is subtle and mimics spongiotic or psoriasiform dermatitis. Every additional year of misdiagnosis represents deferred access to skin-directed therapy and prolonged uncertainty for the patient. A ten-year single-centre dataset is precisely the kind of evidence that quantifies this burden in a specific population, and the Turkish authors frame their work explicitly as an evaluation of clinical and follow-up data, the raw material from which such delays and their consequences can be measured.

Treatment for mycosis fungoides is stage-adapted, and the European Organisation for Research and Treatment of Cancer issued updated consensus recommendations in 2023 that codify the current hierarchy. Early-stage disease is managed with skin-directed therapies: topical corticosteroids and retinoids, phototherapy with narrowband UVB for patches and thin plaques, psoralen plus ultraviolet A for thicker lesions, and localised radiotherapy or total skin electron beam therapy for more extensive or refractory cutaneous involvement. Advanced disease adds systemic options, including interferon-alpha, retinoids such as bexarotene, histone deacetylase inhibitors, antibody-based therapies and, in selected cases, allogeneic stem cell transplantation, the only treatment with potential for durable cure. Combination approaches, pairing a skin-directed modality with a systemic agent, are common in tumour-stage disease. The Istanbul team’s classification of treatments and staging across their cohort maps directly onto this algorithm and illustrates how a high-volume centre deploys it in practice.

Single-centre cohort studies of this kind occupy an important niche in rare-disease research. Randomised trials in mycosis fungoides are difficult to power because the disease is uncommon and its early stages progress slowly, so much of what is known about natural history, treatment patterns and outcomes comes from institutional series accumulated over years or decades. Previous examples include the retrospective analysis of 133 cutaneous lymphoma patients from a single Japanese centre published by Fujita and colleagues, which similarly documented presentation patterns and outcomes over a multi-year window. The Turkish dataset joins this tradition, offering a Mediterranean and Middle Eastern patient population whose demographic profile, referral pathways and treatment access may differ meaningfully from the Northern European and Japanese cohorts that dominate the literature.

The follow-up dimension of the study deserves particular emphasis. Mycosis fungoides can smoulder for decades, and late relapse or transformation to a more aggressive large-cell phenotype can occur years after apparent stability. Longitudinal data from a single centre, where patients are followed by the same diagnostic and therapeutic team, reduce the heterogeneity that plagues multi-site registries, though they also introduce the limitations inherent to retrospective design: reliance on recorded notes, potential loss of patients to follow-up, and the absence of a standardised prospective protocol. The authors’ explicit contribution statement, detailing who diagnosed, biopsied, treated, staged and analysed, underscores the continuity of care that gives such datasets their internal consistency.

For the wider scientific audience, the significance of this research letter lies in what it represents rather than in any single headline number. It demonstrates that cutaneous lymphoma care in Turkey is organised around internationally recognised classification and treatment frameworks, that long-term follow-up is feasible in a public hospital dermatology service, and that the diagnostic bottleneck remains the central challenge of the disease. It also reinforces a message that dermatologists have been repeating for years: persistent, treatment-resistant or unusually distributed skin lesions in adults warrant a low threshold for biopsy and, when histology is equivocal, serial re-biopsy and specialist referral. Earlier recognition will not change the biology of mycosis fungoides, but it moves patients into appropriate surveillance and stage-appropriate therapy sooner, which matters for quality of life and, in the minority who progress, for survival.

The study is available as a research letter in volume 318 of the Archives of Dermatological Research, and its full clinical tables and figures are accessible through the journal. As genomic profiling, targeted immunotherapies and biomarker-driven risk stratification enter the cutaneous lymphoma field, datasets like this one, grounded in a decade of unbroken clinical contact with patients, will serve as the historical baseline against which the next generation of diagnostics and treatments is judged. For now, the Istanbul experience stands as a reminder that in rare lymphomas of the skin, the most powerful clinical instrument remains the patient chart kept faithfully over many years.

Subject of Research: A 10-year single-centre retrospective evaluation of clinical presentation, staging, treatment and follow-up in patients with mycosis fungoides, the most common cutaneous T-cell lymphoma.

Article Title: Evaluation of clinical and follow-up data in patients with mycosis fungoides: a 10-year single-centre experience

Article References: Engin, B., Yildirim, G., & Erkoc, Y. C. (2026). Evaluation of clinical and follow-up data in patients with mycosis fungoides: a 10-year single-centre experience. Archives of Dermatological Research, 318(1), Article 449. https://doi.org/10.1007/s00403-026-04943-7

Image Credits: AI Generated

DOI: 10.1007/s00403-026-04943-7

Keywords: mycosis fungoides, cutaneous T-cell lymphoma, dermatology, WHO-EORTC classification, diagnostic delay, skin biopsy, staging, skin-directed therapy, Sézary syndrome, retrospective cohort study, Istanbul, long-term follow-up

The numbers tell a story of two very different diseases hiding under one diagnostic umbrella. Among the 607 patients classified as high-risk under the European Association of Urology classification, fluorine-18 sodium fluoride PET/CT detected bone metastases in 224 individuals, or 37 percent of the group. Yet among the 127 patients with unfavourable intermediate-risk disease and a tumour grade of ISUP grade group 3, exactly one patient, or 0.8 percent, turned out to have metastatic bone involvement. Follow-up data suggested one additional intermediate-risk patient may have harboured a metastasis that the initial scan missed, but even taking that possibility into account, the yield in this subgroup was vanishingly small.

The imaging technique itself is worth understanding, because its physics explains both its power and its pitfalls. After intravenous injection, the fluoride ion travels through the bloodstream in proportion to regional blood flow and exchanges with hydroxyl ions in hydroxyapatite, the mineral scaffold of bone, to form fluoroapatite. This means the signal captured by the PET camera reflects two biological processes at once: bone perfusion and osteoblastic activity, the cellular machinery that lays down new bone. Bone metastases typically provoke exactly this kind of remodelling, which is why they light up brightly on the scan. The catch is that benign conditions, from arthritis to healing fractures, provoke the same response, so interpretation demands experienced readers who can distinguish malignant patterns from incidental noise.

In this study, ten nuclear medicine specialists who collectively analyse more than 3,000 scans per year interpreted the images. Only 24 of the 734 scans, roughly 3 percent, were classified as equivocal, and two experts blinded to the original reports reanalysed each of those cases to reach a consensus diagnosis, concluding that 20 of the 24 patients did not have bone metastases. That low equivocal rate stands in sharp contrast to the older technology that shaped current guidelines. Planar bone scintigraphy using technetium-99m labelled diphosphonates, the workhorse of previous decades, produces far more ambiguous results. In one retrospective study of 853 patients cited by the Danish team, 16 percent of scans were equivocal; in another of 703 patients, the figure reached 42 percent, forcing a cascade of additional imaging.

To establish how trustworthy the PET findings actually were, the researchers constructed a rigorous reference standard. A nuclear medicine specialist reviewed all available follow-up imaging alongside clinical records, and when the picture remained unclear, a urologic specialist weighed the full clinical data set. Evidence supporting metastatic disease ranged from histologic verification and confirmatory MRI or PSMA PET/CT findings down to patterns of increasing fluoride uptake or newly emerging lesions consistent with treatment failure. Evidence against included undetectable prostate-specific antigen after radical prostatectomy, negative complementary imaging, and consistently negative follow-up scans paired with stable or falling PSA in the absence of systemic therapy. For the 689 patients, 94 percent of the cohort, in whom this process yielded a conclusive verdict, fluorine-18 sodium fluoride PET/CT achieved a sensitivity of 0.90 and a specificity of 0.99, figures the authors describe as consistent with the best previous estimates.

Within the high-risk group, the analysis confirmed what clinicians have long suspected about the biology of prostate cancer’s spread to bone. Higher PSA levels, more advanced clinical tumour stage, and higher ISUP grade groups each carried independently increasing odds of metastasis in multivariate logistic regression, with the three variables adjusted for potential confounding. This dose-response relationship across the classic risk markers reinforces that bone imaging is genuinely informative precisely where the disease is most aggressive. The problem, the authors argue, is that guidelines extrapolated from planar bone scintigraphy-era evidence have never been systematically revalidated for modern scanners, and the diagnostic pathway itself has shifted underneath them, with MRI-targeted biopsies now upgrading many tumours into higher grade categories and shifting patients between risk groups.

The single intermediate-risk patient with a confirmed metastasis illustrates how subtle these cases can be. The scan revealed a single sclerotic lesion in the right pubic bone with avid fluoride uptake, subsequently confirmed by gallium-68 PSMA-11 PET/CT. The patient underwent radical prostatectomy as part of a clinical trial for oligometastatic disease, and histopathology of the removed prostate showed grade group 5 disease, a reminder that grade can be underestimated before the whole gland is examined. The second intermediate-risk patient, whose initial scan showed no lesions, received curative radiotherapy and 17 months of medical castration before treatment was stopped due to side effects; three and a half years later, a follow-up sodium fluoride PET/CT revealed a suspicious lesion in the left pubic bone, and the original scan was retrospectively classified as false-negative.

How do these results square with the newer contender in the field, PSMA PET/CT? A retrospective multicenter study of 396 intermediate-risk patients with grade group 3 disease, examined with four different PSMA radioligands, found bone metastases in 4 percent overall, but the rate varied dramatically by tracer: 21 percent with fluorine-18 PSMA-1007 against just 3 percent with gallium-68 labelled agents. That discrepancy matters because fluorine-18 PSMA-1007 is known to produce uptake in non-specific bone lesions, meaning some of those positives were likely false. A separate study of 1,253 consecutive men staged with gallium-68 PSMA-11 PET/CT detected bone metastases in only 3 percent of 638 intermediate-risk patients. Both figures align closely with the Danish sodium fluoride results, and they carry a practical warning: when the pretest probability of bone involvement is this low, isolated PSMA-avid bone lesions should be interpreted with considerable caution, since non-specific uptake may account for a substantial share of positive findings.

The authors are candid about the limitations that temper their conclusions. The retrospective, single-center design introduces potential selection bias and limits control over imaging indications and follow-up procedures. The reference standard relied on follow-up rather than histology in most cases, leaving room for misclassification, and systemic treatment started after the index scan may have masked metastases that would otherwise have declared themselves. The sensitivity estimate in the intermediate-risk subgroup rested on just two positive patients, making it statistically imprecise. Biopsy technique also varied across the cohort, with some men receiving systematic ultrasound-guided biopsies and others MRI-targeted sampling from March 2019 onward, a heterogeneity that may have influenced ISUP grading and therefore risk stratification itself.

Even with those caveats, the central message is hard to escape. Fluorine-18 sodium fluoride PET/CT performs superbly where it matters most, catching bone metastases in more than a third of high-risk patients with sensitivity and specificity approaching the ceiling of what imaging can achieve. But for men with unfavourable intermediate-risk disease and grade group 3 tumours, the scan found metastases in one patient out of 127, and the authors conclude that routine use in this subgroup appears to have limited clinical value. As hospitals worldwide weigh the cost, radiation exposure, and logistical burden of staging imaging against genuine benefit, this study offers a data-driven argument for narrowing the net, reserving advanced bone imaging for the patients in whom the disease is truly likely to have already reached the skeleton.

Subject of Research: Diagnostic accuracy of fluorine-18 sodium fluoride PET/CT for detecting bone metastases in newly diagnosed prostate cancer

Article Title: Risk of bone metastases on [18F]NaF PET/CT in 734 patients with newly diagnosed prostate cancer

Article References: Madsen, C., Zacho, H. D., Bisbjerg, R., Fuglø, D., & Østergren, P. B. (2026). Risk of bone metastases on [18F]NaF PET/CT in 734 patients with newly diagnosed prostate cancer. European Journal of Nuclear Medicine and Molecular Imaging. https://doi.org/10.1007/s00259-026-08148-y

Image Credits: AI Generated

DOI: 10.1007/s00259-026-08148-y

Keywords: prostate cancer, bone metastases, NaF PET/CT, PSMA PET/CT, bone scintigraphy, diagnostic accuracy, intermediate-risk, ISUP grade group, EAU guidelines, PSA, nuclear medicine, staging

The tracer in question is [¹⁸F] AlF-NOTA-Pentixafor, often abbreviated simply as [¹⁸F] Pentixafor. Unlike FDG, which reports on glucose consumption, Pentixafor homes in on CXCR4, a chemokine receptor that acts as a homing beacon for many cancers of the immune system. CXCR4 is overexpressed on the surface of numerous B-cell malignancies, and it plays a genuine biological role in the disease, guiding malignant cells to particular tissue niches and contributing to their survival and dissemination. A tracer that binds CXCR4 therefore does not merely detect a metabolic side effect of cancer; it detects a molecule the cancer actively deploys. This mechanistic distinction is what makes the new study scientifically interesting, because it asks whether a biologically targeted signal can outperform a metabolic one in a tumor type where metabolism is unreliable.

The study was deliberately framed as exploratory. Twenty patients, eleven men and nine women, all with pathologically confirmed gastric MALT lymphoma, underwent both [¹⁸F] FDG PET/CT and [¹⁸F] Pentixafor PET/CT scans. Scanning each patient with both tracers is the strongest design feature of the work, because it allows head-to-head comparison within the same individuals, eliminating the confounding that arises when different cohorts are compared across studies. The researchers then compared how often each tracer detected gastric lesions, and they measured semiquantitative parameters including SUVmax, SUVmean, and the tumor-to-blood pool ratio, or TBR, for both gastric lesions and any disease that had spread beyond the stomach. A statistical test known as the McNemar test, which is specifically designed for paired comparisons of detection rates in the same subjects, was used to assess whether the difference between the two tracers reached significance.

The headline result was numerically striking even if statistically cautious. [¹⁸F] Pentixafor PET/CT was positive in nine of the twenty gastric lesions, a detection rate of forty-five percent, whereas [¹⁸F] FDG PET/CT flagged only four of twenty, or twenty percent. In other words, the CXCR4-targeted tracer found more than twice as many gastric lesions as the standard metabolic tracer. The median SUVmax among Pentixafor-positive gastric lesions was 4.2, with a range running from 1.1 to 7.2, indicating that uptake intensity varied considerably from patient to patient. Yet when the authors subjected this apparent superiority to formal statistical testing, the difference did not reach significance, a finding the team attributes candidly to the small sample size and the non-matched nature of some of the semiquantitative comparisons. This is a crucial nuance: the study does not prove Pentixafor is better, but it provides the kind of preliminary signal that justifies larger, definitive trials.

Perhaps the most intriguing findings came from the subset of patients whose disease had escaped the stomach. Among the five patients with extragastric disease, [¹⁸F] Pentixafor uptake was numerically higher in the lesions outside the stomach than in the gastric lesions themselves, whereas FDG showed no consistent pattern at all. When the researchers pooled lymph-node and pulmonary lesions, the same trend emerged: these sites took up Pentixafor more avidly than FDG. This observation carries real clinical weight, because the management of gastric MALT lymphoma depends heavily on accurate staging. A patient whose disease appears confined to the stomach may be treated with local approaches such as antibiotics targeting Helicobacter pylori infection or radiotherapy, whereas disseminated disease demands systemic therapy. A tracer that reliably illuminates disease beyond the stomach could therefore change treatment decisions in ways that a marginal improvement in gastric detection alone could not.

The researchers also probed which clinical factors predicted a positive Pentixafor scan. The answer was unexpected and, in some respects, sobering. CT-visible gastric wall abnormality was significantly associated with positive Pentixafor PET/CT findings, with a P value below 0.001, making it the only variable that showed a clear statistical relationship. Age, sex, Lugano classification, and the Ki-67 proliferation index, all factors one might reasonably expect to correlate with tracer uptake, showed no significant associations. The association with CT wall abnormalities cuts both ways. On one hand, it suggests that Pentixafor uptake reflects genuine structural disease rather than noise. On the other hand, as the authors themselves note, it implies that the added benefit of the PET signal over CT alone may be limited: if the CT component already shows the abnormality, the radioactive tracer may be confirming rather than discovering it.

The authors are appropriately careful about the limits of their semiquantitative data. All SUV and TBR values are presented as descriptive statistics, and direct comparisons between the two tracers were not performed because the sample was small and the lesion sets were not fully matched. This restraint matters in a field where tracer enthusiasm can sometimes outrun evidence. Pentixafor has generated considerable excitement in nuclear medicine, with studies exploring its use in multiple myeloma, Waldenström macroglobulinemia, and various lymphomas, but each new tumor type demands its own rigorous evaluation. Gastric MALT lymphoma poses particular challenges for any PET tracer: the lesions are often shallow, diffuse, and low in tracer avidity, and physiological uptake in the stomach wall can obscure genuine pathology. A forty-five percent detection rate, while better than twenty percent, still leaves the majority of gastric lesions invisible to the targeted tracer.

Technically, the study also showcases an elegant radiochemistry approach. [¹⁸F] AlF-NOTA-Pentixafor is produced using the aluminum-fluoride labeling method, in which the fluorine-18 radionuclide is chelated to an aluminum ion that binds to the NOTA chelator conjugated to the Pentixafor peptide. This approach avoids the harsh conditions required for direct fluorination of peptides and allows the tracer to be synthesized from the same cyclotron-produced fluorine-18 that already powers FDG production in hospital radiopharmacies. That practical compatibility is not trivial. A tracer that requires exotic isotopes or complex on-site synthesis faces enormous barriers to clinical adoption, whereas one that can be manufactured with existing infrastructure has a realistic path into routine practice. The choice of fluorine-18 also gives the tracer a half-life of about 110 minutes, long enough for distribution and imaging but short enough to limit patient radiation dose.

What should clinicians and patients take away from this work? The honest answer is that it is a promising first step, not a practice-changing result. The study was conducted in accordance with the Declaration of Helsinki, approved by the Ethics Committee of Sichuan Cancer Hospital, and supported by institutional and national nuclear technology research funding, and the authors declare no competing interests. Its conclusions are explicitly framed as preliminary: Pentixafor detected more gastric lesions than FDG, the difference was not statistically significant, and the association with CT wall abnormalities suggests the tracer’s incremental value over conventional imaging remains to be demonstrated. The research team, led by co-first authors Shirong Chen and Xinyang Li and co-corresponding authors Zhuzhong Cheng and Ying Kou, calls for larger studies to define the clinical role of [¹⁸F] Pentixafor PET/CT in this disease.

Still, the broader scientific story is compelling. The study embodies a shift in nuclear medicine from imaging what cancer does, namely consuming glucose, toward imaging what cancer is, namely a cell bearing specific molecular markers. CXCR4 is one of the most heavily studied receptors in tumor biology, and the ability to visualize it noninvasively opens a window on disease biology that metabolic imaging cannot provide. For gastric MALT lymphoma, a cancer that has long evaded reliable molecular imaging, the preliminary numbers from Chengdu suggest that the CXCR4-targeted approach deserves a larger stage. If future studies with adequate statistical power confirm the trends seen here, particularly the apparent advantage in extragastric and nodal disease, then [¹⁸F] Pentixafor could become a genuine complement to FDG in the staging and surveillance of indolent lymphomas, turning a molecular homing receptor into a diagnostic beacon.

Subject of Research: Comparison of FDG and CXCR4-targeted Pentixafor PET/CT tracers for imaging gastric MALT lymphoma

Article Title: A preliminary evaluation of [¹⁸F] FDG and [¹⁸F] AlF-NOTA-Pentixafor PET/CT in gastric MALT lymphoma

Article References: Chen, S., Li, X., Cheng, Z., & Kou, Y. (2026). A preliminary evaluation of [¹⁸F] FDG and [¹⁸F] AlF-NOTA-Pentixafor PET/CT in gastric MALT lymphoma. BMC Medical Imaging. https://doi.org/10.1186/s12880-026-02816-z

Image Credits: AI Generated

DOI: 10.1186/s12880-026-02816-z

Keywords: gastric MALT lymphoma, PET/CT, [¹⁸F] FDG, [¹⁸F] Pentixafor, CXCR4, molecular imaging, SUVmax, tumor-to-blood pool ratio, non-Hodgkin lymphoma, staging, radiopharmaceuticals, BMC Medical Imaging

The numbers reported by the research team are striking. Among 49 patients with renal medullary carcinoma who underwent 18F-FDG PET/CT scans at MD Anderson between 2016 and 2025, the radiotracer detected lesions in 98 percent of cases, or 48 of the 49 patients. Even more consequential, in 65 percent of patients the tracer revealed additional cancer lesions that were not visualized on standard anatomical imaging such as computed tomography or magnetic resonance imaging. Those extra findings were not merely academic curiosities: in 21 percent of patients with active disease, the PET/CT results directly changed the clinical management plan, steering physicians away from treatments that would have been futile or harmful and toward strategies better matched to the true extent of disease.

Renal medullary carcinoma is a disease that demands precision from the very first scan. It predominantly affects adolescents and young adults, occurs more often in males, and is strongly associated with sickle cell trait and related hemoglobinopathies, conditions in which the oxygen-carrying environment of the renal medulla appears to create conditions favorable to tumor development. At the time of diagnosis, patients frequently already present with metastatic disease, and the median overall survival is approximately 14.5 months. Against that grim backdrop, every staging decision carries enormous weight. Surgery that might offer curative potential in localized disease becomes a source of suffering and delay when the cancer has in fact spread undetected, because high-morbidity operations postpone the systemic therapies that metastatic patients urgently need.

Simone Krebs, MD, MS, a nuclear medicine physician and scientist at MD Anderson and the study’s lead author, emphasized just how much rides on getting staging right in this disease. In renal medullary carcinoma, she noted, the value of accurate staging cannot be overstated, because upstaging a patient from localized to metastatic disease spares them from noncurative, high-morbidity surgeries that would only delay the initiation of essential systemic therapy. Identifying metastatic disease, she added, may also open opportunities for more effective therapies tailored to a patient’s actual disease burden. Her comments underscore a central tension in oncology: the difference between what imaging shows and what the cancer is actually doing can determine whether a patient receives the right treatment at the right time or loses precious months to the wrong one.

The biological basis for the study’s success lies in the way renal medullary carcinoma handles glucose. 18F-FDG is a glucose analog labeled with fluorine-18; it is taken up by cells through glucose transporters and then becomes metabolically trapped, allowing positron emission tomography to visualize tissues with high glycolytic activity. Many cancers are avid for FDG, but uptake varies considerably across kidney tumor subtypes, which has historically limited the tracer’s reputation in urologic oncology. Clear cell renal cell carcinoma, the most common kidney cancer, often shows variable FDG uptake, and some renal lesions are better characterized by other tracers or by dedicated CT protocols. Renal medullary carcinoma, however, demonstrates strong and consistent FDG uptake, distinguishing it from other kidney cancers and making it an unusually suitable target for FDG PET/CT imaging.

That metabolic avidity translated into practical diagnostic power even in patients who had already begun systemic treatment. The study found that 18F-FDG PET/CT remained highly effective after therapy had been initiated, an important point because treatment can alter tumor metabolism and degrade the performance of metabolic imaging in some cancers. In renal medullary carcinoma, the tracer continued to illuminate active disease, giving oncologists a reliable way to assess how patients were responding and whether residual lesions represented viable tumor. Quantitative PET/CT metrics were evaluated alongside visual interpretation, and the researchers systematically recorded every instance in which imaging findings altered treatment, providing a structured account of the scan’s real-world impact rather than anecdotal impressions.

The clinical consequences of the additional findings were often dramatic. In one illustrative case included in the published work, a patient demonstrated intense focal FDG uptake in nodal, hepatic, soft-tissue, and osseous metastases on maximum-intensity-projection imaging. Axial FDG PET and fused PET/CT images revealed focal intense uptake in the right iliac bone, a finding without a definite correlate on the dedicated CT image. That discrepancy, a metabolically active lesion invisible on anatomical imaging, led directly to changes in the patient’s clinical management. It is precisely this pattern, PET revealing disease that CT cannot confirm, that explains how the tracer upstaged so many patients and redirected so many treatment plans in the study cohort.

For patients, the implications of these findings are potentially life-altering. A young adult with renal medullary carcinoma who appears to have localized disease on a conventional CT scan might, in fact, harbor hepatic, nodal, or bone metastases that only PET/CT can reveal. Detecting those lesions before surgery could spare the patient a major operation that would never have been curative, while simultaneously accelerating access to systemic therapy, the treatment modality most likely to extend survival in metastatic disease. Conversely, for patients whose PET/CT confirms truly limited disease, the scan provides confidence that aggressive local treatment is justified. In both directions, the additional information changes decisions, and in a cancer with a median survival measured in months, better decisions translate directly into better use of the limited time available.

The study’s authors argue that the evidence now justifies a formal change in clinical practice. Their conclusion is that the findings may support the inclusion of 18F-FDG PET/CT in upcoming guidelines regarding renal medullary carcinoma, which would enable broader clinical use beyond specialized centers like MD Anderson. Guideline inclusion matters because renal medullary carcinoma is rare enough that many treating institutions will encounter only a handful of cases, and clinicians may default to conventional staging pathways unless professional society recommendations explicitly endorse metabolic imaging. Krebs and her colleagues contend that PET/CT provides clinically meaningful information beyond conventional imaging, helping doctors better assess the extent of disease and choose the most appropriate treatment strategy, and that on a larger scale the research supports wider adoption in routine patient care.

As molecular imaging continues to expand its role in oncology, the MD Anderson study offers a compelling case study in how an old, proven tool can find new purpose in an underserved disease. 18F-FDG has been a staple of nuclear medicine for decades, yet its value in kidney cancer has been considered limited and subtype-dependent. By rigorously documenting its performance specifically in renal medullary carcinoma, a population of predominantly young patients with few good options, the researchers have turned a routine radiotracer into a potential standard of care for one of oncology’s most aggressive diagnoses. With 98 percent detection, additional lesions found in nearly two-thirds of patients, and management changes in one in five, the case for FDG PET/CT in this disease is difficult to ignore, and the coming updates to clinical guidelines may soon make this powerful scan a routine part of the fight against renal medullary carcinoma.

Subject of Research: Use of 18F-FDG PET/CT imaging for staging and treatment planning in renal medullary carcinoma

Article Title: Proven radiotracer highly effective in detecting rare, aggressive kidney cancer

Article References: Proven radiotracer highly effective in detecting rare, aggressive kidney cancer. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: renal medullary carcinoma, 18F-FDG PET/CT, kidney cancer, molecular imaging, metastatic disease, staging, nuclear medicine, radiotracer, MD Anderson Cancer Center, treatment planning, non-clear cell renal cell carcinoma, Journal of Nuclear Medicine